SMTL ID : 7k90.1

Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144

Coordinates

PDB Format

Method

ELECTRON MICROSCOPY

Oligo State

hetero-3-3-3-mer

Ligands

33 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.1: 3 residues within 4Å: Chain A: N.122, N.125, V.127 Ligand excluded by PLIP NAG.2: 2 residues within 4Å: Chain A: N.165, T.167 Ligand excluded by PLIP NAG.3: 2 residues within 4Å: Chain A: N.280, N.282 Ligand excluded by PLIP NAG.4: 2 residues within 4Å: Chain A: N.331, I.332 Ligand excluded by PLIP NAG.5: 1 residues within 4Å: Chain A: N.603 Ligand excluded by PLIP NAG.6: 2 residues within 4Å: Chain A: N.616, T.618 Ligand excluded by PLIP NAG.7: 1 residues within 4Å: Chain A: N.657 Ligand excluded by PLIP NAG.8: 2 residues within 4Å: Chain A: N.709, G.1131 Ligand excluded by PLIP NAG.9: 3 residues within 4Å: Chain A: N.717, Q.926, Q.1071 Ligand excluded by PLIP NAG.10: 3 residues within 4Å: Chain A: N.1098, H.1101, F.1103 Ligand excluded by PLIP NAG.11: 1 residues within 4Å: Chain A: N.1134 Ligand excluded by PLIP NAG.12: 3 residues within 4Å: Chain B: N.122, N.125, V.127 Ligand excluded by PLIP NAG.13: 2 residues within 4Å: Chain B: N.165, T.167 Ligand excluded by PLIP NAG.14: 2 residues within 4Å: Chain B: N.280, N.282 Ligand excluded by PLIP NAG.15: 2 residues within 4Å: Chain B: N.331, I.332 Ligand excluded by PLIP NAG.16: 1 residues within 4Å: Chain B: N.603 Ligand excluded by PLIP NAG.17: 2 residues within 4Å: Chain B: N.616, T.618 Ligand excluded by PLIP NAG.18: 1 residues within 4Å: Chain B: N.657 Ligand excluded by PLIP NAG.19: 2 residues within 4Å: Chain B: N.709, G.1131 Ligand excluded by PLIP NAG.20: 3 residues within 4Å: Chain B: N.717, Q.926, Q.1071 Ligand excluded by PLIP NAG.21: 3 residues within 4Å: Chain B: N.1098, H.1101, F.1103 Ligand excluded by PLIP NAG.22: 1 residues within 4Å: Chain B: N.1134 Ligand excluded by PLIP NAG.23: 3 residues within 4Å: Chain C: N.122, N.125, V.127 Ligand excluded by PLIP NAG.24: 2 residues within 4Å: Chain C: N.165, T.167 Ligand excluded by PLIP NAG.25: 2 residues within 4Å: Chain C: N.280, N.282 Ligand excluded by PLIP NAG.26: 2 residues within 4Å: Chain C: N.331, I.332 Ligand excluded by PLIP NAG.27: 1 residues within 4Å: Chain C: N.603 Ligand excluded by PLIP NAG.28: 2 residues within 4Å: Chain C: N.616, T.618 Ligand excluded by PLIP NAG.29: 1 residues within 4Å: Chain C: N.657 Ligand excluded by PLIP NAG.30: 2 residues within 4Å: Chain C: N.709, G.1131 Ligand excluded by PLIP NAG.31: 3 residues within 4Å: Chain C: N.717, Q.926, Q.1071 Ligand excluded by PLIP NAG.32: 3 residues within 4Å: Chain C: N.1098, H.1101, F.1103 Ligand excluded by PLIP NAG.33: 1 residues within 4Å: Chain C: N.1134 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Barnes, C.O. et al., SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature (2020)

Release Date

2020-10-21

Peptides

Spike glycoprotein: ABC
C144 Fab Heavy Chain: DEF
C144 Fab Light Chain: GHI

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
C

D
H

E
M

F
O

G
L

H
N

I
P

Spike glycoprotein

C144 Fab Heavy Chain

C144 Fab Light Chain

Related Entries With Identical Sequence